Login to Your Account



Potential 'Blockbuster Status'

Algeta-Bayer Prostate Cancer Metastases Trial is Stopped

By Nuala Moran


Tuesday, June 7, 2011
LONDON – Algeta A/S said its lead product Alpharadin is on course for blockbuster status after the Phase III trial was stopped on the basis of statistically significant efficacy in the treatment of bone marrow metastases in patients with castration-resistant prostate cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription